European health regulators on Friday conditionally approved Amgen Inc"s rare blood cancer drug, Blincyto, which is one of the world"s most expensive cancer treatments. The U.S. Food and Drug Administration in December approved Blincyto for acute lymphoblastic leukemia (ALL), which has few treatment options once a patient has relapsed.
Amgen"s leukemia drug gets conditional European approval
Friday, 25 September 2015
Amgen"s leukemia drug gets conditional European approval
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment